ライフサイエンスコーパス: inhaler

1 and a nicotine replacement therapy (Nicotine inhaler).

2 red adherence (number of doses left in study inhalers).

3 who overrely on their reliever beta-agonist inhaler.

4 ts were delivered via the ELLIPTA dry powder inhaler.

5 inistered through a pressurized metered-dose inhaler.

6 er inhalers (DPI's) varies with the specific inhaler.

7 ts (81%) reported benefit from the albuterol inhaler.

8 lung after administration from the Azmacort inhaler.

9 nsisted of two capsules administered with an inhaler.

10 inhaler vs fluticasone-salmeterol dry-powder inhaler.

11 CI, 0.98 to 1.14) compared to the dry powder inhaler.

12 ly for 52 weeks via pressurised metered-dose inhaler.

13 n treatment to triple therapy using a single inhaler.

14 th different mechanism of action in a single inhaler.

15 on plan and coaching in proper use of asthma inhalers.

16 y pulmonary deposition patterns from aerosol inhalers.

17 play, and can potentially be administered as inhalers.

18 COPD were accessing appropriate maintenance inhalers.

19 improved cost-effectiveness versus multiple inhalers.

20 g-acting beta-agonist (ICS-LABA) combination inhalers.

21 lkane (HFA)-152a, against current salbutamol inhalers.

22 % of all follow-up time compared to 0.5% for inhalers.

23 ion for symptoms due to misperceptions about inhalers.

24 ticosteroids and 2 or fewer dispensed rescue inhalers.

25 e the delivery to the airways via dry powder inhalers.

26 e level of commercially available dry powder inhalers.

27 eated with pollen AIT, the OR of using nasal inhaler 0-5 years after baseline was reduced when compar

28 her degree stopped using anti-allergic nasal inhaler 0-5 years after starting the standard 3 years of

29 e in the mean FEV(1 )while using the placebo inhaler (1.70 L versus 1.60 L, baseline versus placebo:

30 ctively; P=0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per week, respectively;

31 Patients received IB by metered-dose inhaler (40mug per dose) with a spacer three times at 20

32 albuterol inhaler (50% improvement), placebo inhaler (45%), or sham acupuncture (46%), but the subjec

33 d not differ significantly for the albuterol inhaler (50% improvement), placebo inhaler (45%), or sha

34 asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no inte

35 safety of combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART) wi

36 A total of 152 schools (66%) used a stock inhaler, accounting for 1038 events.

37 Combination LAMA-LABA inhalers (aclidinium-formoterol, glycopyrronium-formoter

38 budesonide (with each dose consisting of two inhaler actuations of 90 mug and 80 mug, respectively) o

39 albuterol (with each dose consisting of two inhaler actuations of 90 mug) on an as-needed basis for

40 The difference in the program's effect on inhaler adherence between Black and White individuals wa

41 ed medication management services had higher inhaler adherence compared with the control group.

42 Inhaler adherence measured as proportion of days covered

43 -dose inhaler (Advair HFA) versus dry powder inhaler (Advair Diskus) among patients with COPD treated

44 casone-salmeterol delivered via metered-dose inhaler (Advair HFA) versus dry powder inhaler (Advair D

45 50 mug, with salmeterol, 25 mug; or placebo inhalers, all given as 2 puffs twice daily for 12 weeks.

46 her doses, differing potency claims, and new inhalers also affect the potential for systemic effects

47 cerbations (daily symptoms and use of rescue inhalers) among 990 children in eight North American cit

48 ing 12 months, 207 (53%) started their study inhaler and 46 (12%) started prednisolone--22 (11%) of 1

49 TIO was delivered via the HandiHaler inhaler and all other active treatments were delivered v

50 ears; 91% male), among patients who switched inhalers and experienced the adverse outcomes of interes

51 am that reduced cost sharing for maintenance inhalers and provided medication management services had

52 plants in archaeological bone tubes used as inhalers and the northernmost direct evidence of vilca a

53 combination of nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63).

54 le, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride.

55 control medications, overuse of quick-relief inhalers, and a significant number of self-reported asth

56 for the development of a medical cannabinoid inhaler; and recommends that compassionate use of mariju

57 Metered-dose inhalers are associated with substantially higher greenh

58 Breath-actuated inhalers are easier to use than pMDIs.

59 automatically detect when patients use their inhalers (area under the curve (AUC) = 0.992) or insulin

60 beta-agonist or ICS/long-acting beta-agonist inhaler as a reliever rather than regular maintenance us

61 ercise was increased while using the placebo inhaler as compared with baseline, and decreased during

62 eta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older chil

63 inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group)

64 bination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild ast

65 chewing gum, skin patches, nasal sprays, and inhalers, as well as pharmacotherapies such as mecamylam

66 Mean total carbon footprint per salbutamol inhaler (based on 100-year global warming potential [GWP

67 Veterans who were prescribed a combination inhaler before and after the formulary change were inclu

68 tion for a combination LAMA-LABA or ICS-LABA inhaler between January 1, 2014, and December 31, 2019.

69 idinium-vilanterol) and combination ICS-LABA inhalers (budesonide-formoterol, fluticasone-salmeterol,

70 Ten metered-dose inhaler canisters were used to administer 2000 microgram

71 risk that the lactose-containing dry powder inhalers cause allergic reactions for patients with cow'

72 The rationale behind inhaler choice should be evidence based rather than empi

73 receiving treatment at steps 3 to 5: single inhaler combination inhaled corticosteroid-formoterol as

74 gned this study to assess efficacy of single-inhaler combination of an extra fine formulation of becl

75 f asthmatic children concerning their use of inhalers, compliance to preventers and to measure its ef

76 eling and the prescription of a metered-dose inhaler containing either ipratropium bromide or placebo

77 In addition, the use of a single inhaler containing ICS and a quick-acting beta2AR agonis

78 This was particularly true for inhalers containing corticosteroids.

79 ) and long-acting beta-agonists (LABAs) over inhalers containing inhaled corticosteroids (ICSs) and L

80 structive pulmonary disease (COPD) recommend inhalers containing long-acting muscarinic antagonists (

81 prescribing of less environmentally friendly inhalers, contrary to national prescribing guidelines.

82 pocket costs and improper use of maintenance inhalers contribute to poor outcomes among patients with

83 Half of the mothers (50%) did not use the inhaler correctly.

84 -dose inhalers to propellant-free dry-powder inhalers could reduce health care-related greenhouse gas

85 We conclude that Spiros and Ventolin inhalers deliver comparable quantities of albuterol to t

86 in vivo efficacy, suitability for dry powder inhaler development, favorable pharmacokinetics, and saf

87 apy (ICS/LABA/LAMA) formulations in a single-inhaler device (SITT) have been investigated in patients

88 Dosage, type of inhaler device used, patient technique, and characterist

89 When choosing an inhaler device, it is essential that it is easy to use c

90 Es) using three different FDA-approved human inhaler devices followed by interaction parameter analys

91 ide variety of reasons, but incorrect use of inhaler devices is amongst the most common.

92 systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3.

93 (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose = 0.86, 0.77-0.93, p < 0.001; ICS mean dail

94 s (adjusted odds ratio, 95% CI, p-value: ICS inhaler dose = 0.99, 0.98-1.00, p = 0.59; ICS mean daily

95 dose (halving their mean-daily dose or their inhaler dose).

96 uggested that we should instruct patients to inhaler DPI based on inspiratory resistance of the DPI.

97 ccessfully designed and developed dry powder inhaler (DPI) formulations of TMC (2-trifluoromethyl-2'-

98 Flow resistance of dry powder inhaler (DPI) is important information when physician ch

99 ative delivery system, the Spiros dry-powder inhaler (DPI), with Ventolin, using a methacholine chall

100 152a and HFA-134a, and salbutamol dry-powder inhaler (DPI).

101 e optimal inhalation effort using dry powder inhalers (DPI's) varies with the specific inhaler.

102 Because dry powder inhalers (DPI) aerosolize agents by means of inspiration

103 or flow instruction in the use of dry powder inhalers (DPI).

104 orofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered

105 However, the development of dry powder inhalers (DPIs), particularly for FDCs, faces challenges

106 f micro/nano-particles, transdermal patches, inhalers, drug reservoir implants and antibody-drug conj

107 e prescription items dispensed for different inhaler drugs in England at Lower Layer Super Output Are

108 odds ratio (OR) of using anti-allergic nasal inhaler during the pollen season in the treated versus n

109 s: inhaler therapy at entry; commencement of inhalers during follow-up; death from respiratory causes

110 Metered-dose inhalers employ propellants to produce pharmaceutical ae

111 ng fluticasone-salmeterol via a metered-dose inhaler (exposure) were compared to those receiving thes

112 port on two studies that compared the single-inhaler extrafine combination of beclometasone dipropion

113 ome from the IMPACT trial, once-daily single-inhaler FF/UMEC/VI triple therapy reduced the risk of AC

114 nt difference in exacerbations, short-acting inhaler fills, or total spending.

115 derate-to-severe exacerbations, short-acting inhaler fills, total spending, and as an exploratory out

116 dred twenty-one subjects used a quick-relief inhaler for asthma symptoms, and 14.6% used more than 3

117 Short-acting inhalers for "rescue therapy" were not evaluated.

118 Prescribing of inhalers for asthma and chronic obstructive pulmonary di

119 m the corresponding pressurized metered-dose inhaler formulations (pMDIs) that have excellent aerosol

120 vailable in both metered-dose and dry powder inhaler formulations for the treatment of chronic obstru

121 tched to a fluticasone-salmeterol dry-powder inhaler had no difference in mortality (1.89% vs 1.90%;

122 rporating two or three medicines in a single inhaler have been created to enhance patient compliance

123 mmatory and reliever medications in a single inhaler have the potential to overcome these limitations

124 Inhaled corticosteroids and other inhalers have been integral in treating many symptoms of

125 ven the added climate impact of metered dose inhalers, health systems seeking to decrease use of thes

126 her greenhouse gas emissions than dry powder inhalers; however, data on their comparative effectivene

127 Most of the mothers (69%) did not use the inhaler if symptoms were mild and 53% didn't use prevent

128 ne years of use, and in patients using nasal inhaler in the latest pollen season (0-2 years, OR 0.76

129 atients who had not used an albuterol rescue inhaler in the past week were compared to those who had

130 a history of wheezing or use of respiratory inhalers in the last 12 months.

131 ronchodilator administration by metered-dose inhaler is becoming the preferred therapy for treating m

132 clinicians in understanding why a prescribed inhaler is not effective and to devise strategies to pro

133 clinical trials comparing these combination inhalers (LAMA-LABAs vs ICS-LABAs) have been conflicting

134 The Single combination budesonide-formoterol inhaler Maintenance And Reliever Therapy (SMART) regimen

135 Unlike inhaler manufacturers, which relied heavily on device pa

136 (15-microg dose) and 200 microg metered-dose inhaler (MDI) albuterol.

137 orofluorocarbon (CFC)-propelled metered-dose inhaler (MDI) during mechanical ventilation, obtained by

138 y and efficacy of a ciclesonide metered-dose inhaler (MDI) for treating nonhospitalized participants

139 l bronchodilator therapy with a metered-dose inhaler (MDI) in intubated, mechanically ventilated pati

140 haling racemic albuterol with a metered-dose inhaler (MDI) is not known.

141 lude swallowed fluticasone from a multi-dose inhaler (MDI) or oral viscous budesonide (OVB) slurry, b

142 medication knowledge and worse metered-dose inhaler (MDI) technique, the relationship between health

143 of aerosol administration by a metered-dose inhaler (MDI), we measured serum albuterol levels after

144 delivered through a combination metered dose inhaler (MDI), with one extra actuation as needed for re

145 ess the use of beta-agonists by metered dose inhaler (MDI).

146 luticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC),

147 ures on albuterol delivery from metered-dose inhalers (MDIs) and jet nebulizers in an in vitro model

148 In nonintubated patients, metered-dose inhalers (MDIs) are accepted as the most convenient, eff

149 tospheric ozone, CFC-containing metered-dose inhalers (MDIs) such as Ventolin and Proventil are being

150 Aerosols from metered dose inhalers (MDIs) with these propellants become electrical

151 ns, quality of life, and use of metered dose inhalers (MDIs), may be related to this difference in re

152 tion of 180 microg albuterol by metered dose inhaler, mean Qaw increased by 83 +/- 26% in normal subj

153 he comparative efficacy of extra-fine single-inhaler medium-dose (MD) or high-dose (HD) of beclometas

154 Paired patient-inhaler metagenomes were compared (n = 31) to assess for

155 ata from an intervention study of electronic inhaler monitoring devices, comprising 211 patients yiel

156 Inhaler monitors recorded fluticasone propionate/salmete

157 r OVB (1 mg/4 mL) twice daily plus a placebo inhaler (n = 56) or fluticasone MDI (880 mug) twice dail

158 rly generic entry), compared to 14 years for inhalers (n=53).

159 ols produced from aerosol generators such as inhalers, nebulizers etc.

160 nic nicotine delivery systems, or a nicotine inhaler (NICOTROL)] The uptake route in the model was de

161 defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less.

162 The SMART therapy using combined inhaler of budesonide (ICS) with formoterol (LABA) was e

163 nhalation per day via single-dose dry-powder inhaler of open-label 18 mug tiotropium, patients were r

164 g) or placebo, both delivered by a soft-mist inhaler once daily for 48 weeks.

165 d antibiotics, 40 (22%) required respiratory inhaler or nebulizer treatments, 41 (22%) used supplemen

166 medication delivery involves devices such as inhalers or insulin pens.

167 with a shorter-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatment beyond 12

168 Significant patient-inhaler overlap in airway microbiomes and their resistom

169 ntaneous nebulizers (p = .001), metered dose inhalers (p = .01), and pulse oximetry (p = .02).

170 s by using a single albuterol inhaler (stock inhaler) paired with a disposable holding chamber.

171 he adjusted invitation effect on maintenance inhaler PDC was 5.5 percentage points (95% CI, 3.3-7.7),

172 The pressurised metered-dose inhaler (pMDI) is still the most frequently used device

173 desonide/formoterol pressurized metered-dose inhaler (pMDI) versus budesonide over 1 year in African

174 GHG emissions, with pressurised metered-dose inhalers (pMDIs) a significant contributor owing to thei

175 ck test showed positive reactions for Inavir inhaler powder and lactose used as an excipient but nega

176 The lactose excipient in Inavir inhaler powder was supposed to contain milk proteins, wh

177 paring two brand-name fluticasone-salmeterol inhalers prescribed for COPD in routine clinical practic

178 d with higher rates of emergency or 'rescue' inhaler prescribing - a pattern that was interrupted dur

179 Inhaler prescribing metrics are valuable for analysing t

180 ed HR, 1.22 [95% CI, 1.11-1.34]), salbutamol inhaler prescription at age 5 years (10.34% vs 9.62%; di

181 hma requiring hospital admission, salbutamol inhaler prescription at age 5 years, and all-cause death

182 dmission; secondary outcomes were salbutamol inhaler prescription at age 5 years, obesity at age 5 ye

183 hma requiring hospital admission, salbutamol inhaler prescription at age 5 years, obesity at age 5 ye

184 ating different combination ICS/beta-agonist inhaler products prescribed according to this regimen in

185 ilarity of in vivo performance of dry powder inhaler products.

186 tators, as well as satisfaction with a stock inhaler program across K through12 schools in Pima Count

187 With technical assistance, stock inhaler programs can be feasibly implemented by schools

188 k or directly intranasal with two dry powder inhalers, PuffHaler and BD Solovent.

189 those receiving these drugs via a dry powder inhaler (referent), with stabilized inverse probability

190 ide/formoterol inhaler according to a single inhaler regimen (SMART) with a fixed-dose regimen with s

191 ial, with GP as unit of cluster, we compared inhaler reminders and feedback (IRF) and/or personalized

192 Inhaler reminders offer an effective strategy for improv

193 Particle release patterns of both dry powder inhalers resembled each other.

194 Feasibility of deploying inhaler sensors to identify the impacts of environmental

195 We found that the inhaler sensors were feasible in passively collecting ob

196 eatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention.

197 livered at a dose of 5 mug with the Respimat inhaler showed efficacy similar to that of 18 mug of tio

198 terol in combination with an ICS in a single inhaler (single maintenance and reliever therapy) is rec

199 ultiple students by using a single albuterol inhaler (stock inhaler) paired with a disposable holding

200 ion), five denied nonadherence, two had poor inhaler technique (unintentional nonadherence), and one

201 ment plan (SMP) [0.554 (0.515; 0.593)], poor inhaler technique [0.53 (0.475; 0.585)], poor medication

202 navigational ability are likely to have poor inhaler technique and limited understanding of ICS funct

203 Inhaler technique improved substantially in both groups.

204 care alone; all GPs received action plan and inhaler technique training.

205 ntions reported significant improvements for inhaler technique, adherence and quality of life.

206 asic management needs, such as adherence and inhaler technique, are corrected) or true, therapy-resis

207 ristics (including self-management plan use, inhaler technique, medication compliance) appear to be t

208 brief introduction of aerosol properties and inhaler technology is followed by considerations of in v

209 aily, the challenge is to develop a combined inhaler that can be employed on a daily basis.

210 this might be addressed by using combination inhalers that contain a corticosteroid and long-acting b

211 r IgA titer and any of the outcome measures: inhaler therapy at entry; commencement of inhalers durin

212 ively quantify adherence to preventer Diskus inhaler therapy by patients with COPD with an electronic

213 Inhaler therapy is the backbone of treatment and should

214 tment with fluticasone-salmeterol dry-powder inhaler therapy was associated with a 10% decrease in al

215 sis of symptomatic asthma and on maintenance inhaler therapy were randomly assigned to initiate treat

216 y treated with triple fixed-dose combination inhaler therapy with an inhaled corticosteroid, long-act

217 sis of symptomatic asthma and on maintenance inhaler therapy, initiation of a once-daily treatment re

218 mployed by manufacturers of nebulizer versus inhaler therapy.

219 Immediately after release from the inhaler, they reached the peak value and then completed

220 tion from budesonide-formoterol metered-dose inhaler to fluticasone-salmeterol dry-powder inhaler was

221 a connected weight scale, a sensor-attached inhaler to monitor adherence, a lung function monitor, a

222 ts added an active or placebo corticosteroid inhaler to their usual corticosteroid for 14 days to pro

223 am that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management

224 Transitioning from metered-dose inhalers to propellant-free dry-powder inhalers could re

225 Electronic sensors fitted on metered dose inhalers tracked 5,660 rescue inhaler use events in spac

226 during the trial could be attributed to the inhaler treatment.

227 , with and without BPD; and before and after inhaler treatment.

228 One child developed cough when starting inhaler treatment; no other adverse events reported duri

229 Compared to relevant single-inhaler triple therapies, MD and HD BDP/FOR/GLY are asso

230 Among single-inhaler triple therapies, MD BDP/FOR/GLY significantly r

231 eek global study comparing once-daily single-inhaler triple therapy (fluticasone furoate-umeclidinium

232 These results support the benefits of single-inhaler triple therapy compared with ICS/LABA therapy in

233 A single-inhaler triple therapy containing extrafine formulations

234 studies have assessed the efficacy of single-inhaler triple therapy in asthma.

235 e IMPACT trial showed that once-daily single-inhaler triple therapy significantly reduced exacerbatio

236 Single-inhaler triple therapy was associated with decreased hea

237 matched pairs of new users initiating single inhaler triple therapy.

238 to 180 mug or 200 mug budesonide dry powder inhaler twice daily for the entire duration of the study

239 = 1812) or placebo (n = 1818) by dry-powder inhaler, twice daily for up to 3 years.

240 dability was calculated in ten studies: SABA inhalers typically cost around 1-4 days' wages, ICSs 2-7

241 tion and ED visits, six or more beta-agonist inhalers (units) during the prior 6 mo, and three or mor

242 increased by 0.1 to 0.3/1,000 spores/m3) and inhaler use (0.1 to 0.4 puffs/1,000 spores/m3) across sp

243 Additionally, inhaler use (OR, 1.6; 95% CI, 1.2-2.5), depression/anxie

244 but not 1-h maximum O3, was associated with inhaler use (p < 0.03).

245 hese data provide an accurate measurement of inhaler use and allow spatially and temporally resolute

246 Cluster 2 (25%) had high inhaler use and high error rates.

247 Cluster 1 (34%) had low inhaler use and high error rates.

248 Concomitant rescue beta-agonist inhaler use and the need for corticosteroid rescue are a

249 t environment factors associated with rescue inhaler use and to determine whether these findings woul

250 weekly exposure to PM(2.5) increases weekly inhaler use by 0.82%.

251 and Poisson hurdle regression examined stock inhaler use by school organization type, grade levels se

252 (-0.42% [CI, -3.74% to 2.91%]), symptoms, or inhaler use compared with placebo but maintained an 8.74

253 to test the feasibility of collecting rescue inhaler use data in space-time using electronic sensors.

254 ble in passively collecting objective rescue inhaler use data.

255 oms (functional levels 0 to 5) and as-needed inhaler use during September and October 1993 in San Die

256 n metered dose inhalers tracked 5,660 rescue inhaler use events in space and time for 140 participant

257 reless sensor to track the place and time of inhaler use events, as well as regular nonevent location

258 ing a sensor to capture the signal of rescue inhaler use in space-time offered a passive and objectiv

259 ores increased by 25% (95% CI: 0 to 49%) and inhaler use increased by 26% (95% CI: 3 to 48%) over the

260 espectively, and with rate ratios for rescue inhaler use of 1.06 (95% CI: 1.01, 1.10) and 1.05 (95% C

261 21% found inhaler use unacceptable.

262 use (B2-adrenergic agonist inhaler) whereby inhaler use was four times more likely during the circad

263 models to identify triggers associated with inhaler use, and implemented three sensitivity analyses

264 KL-40 had significantly more frequent rescue-inhaler use, greater oral corticosteroid use, and a grea

265 a positive and significant association with inhaler use, including: AQI, PM10, weed pollen, and mold

266 he causal relationship between pollution and inhaler use.

267 or the Asthma Control Test scores and rescue inhaler use.

268 a negative and significant association with inhaler use.

269 quantified the frequency and proficiency of inhaler use.

270 th a short-acting beta-agonist as a separate inhaler used when needed for symptom relief.

271 ort of 1.1 million intranasal corticosteroid inhaler users (proxy for AR), we matched users treated w

272 ment with budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powder inhaler.

273 e of fluticasone-salmeterol via metered-dose inhaler was associated with a similar hazard of first mo

274 inhaler to fluticasone-salmeterol dry-powder inhaler was associated with increased health care utiliz

275 The PDC for maintenance inhalers was higher in the invited group than the contro

276 Electronic monitoring of inhalers was used to measure medication use.

277 orporated long-acting beta(2)-agonist (LABA) inhalers were included.

278 and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessa

279 ill required significant use of quick-relief inhalers, whereas 28% had never used long-term control m

280 ue bronchodilator use (B2-adrenergic agonist inhaler) whereby inhaler use was four times more likely

281 Conventional coarse-particle inhalers, which emit particles larger than 2 mum, might

282 tecting the dose delivered from a dry powder inhaler while sampling for aerodynamic particle size dis

283 given liquid dextromethorphan and albuterol inhaler with a spacer.

284 28) or placebo (n = 13) using a metered-dose inhaler with a spacer.

285 patients were given a salmeterol/fluticasone inhaler with an INCA device attached.

286 We aimed to investigate whether use of an inhaler with audiovisual reminders leads to improved adh

287 with 400 mug of salbutamol in a metered-dose inhaler with or without a spacer, variability in peak ex

288 nitoring device for use with their preventer inhaler with the audiovisual reminder functions either e

289 s to be dispensed to schools, and suggesting inhalers with valved holding chambers/spacers for admini

290 /vilanterol 100 mug/62.5 mug/25 mug; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/f

291 ination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone

292 d patients prescribed combination controller inhalers, with suboptimal Asthma Control Test (ACT) scor